Atossa Therapeutics, Inc. ATOS
Regular-session close
After hours · Nov 16, 4:00 PM ET
- YTD
- -78.19%
- 1 year
- -83.92%
- Market cap
- 19.26M
- EPS (ttm)
- -4.00
- Shares out
- 125.80M
- Forward P/E
- -3.81
- YTD return
- -78.19%
- 1-year return
- -83.92%
- 50-day average
- 1.31
- 200-day average
- 1.39
- Enterprise value
- 46.47M
- Volume
- 69.55K
- Avg volume
- 70.74K
- Open
- 1.98
- Previous close
- 1.96
- Day's range
- 1.86 – 2.09
- 52-week range
- 1.70 – 14.85
- Beta
- 1.23
- Analysts
- Strong Buy
- Price target
- 6.00 (+210.9%)
5D -0.26 (-11.82%)
Key statistics
- Price / book
- 1.76
- Free cash flow
- -12.76M
- Total cash
- 74.77M
- Return on equity
- -31.30%
- Short % of float
- 9.23%
Fundamental scorecard
6 of 25 checks passed on ATOS’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.06 | -0.05 | +0.01 | +16.67% |
| Aug 12, 2024 | Jun 1, 2024 | -0.05 | -0.05 | 0.00 | 0.00% |
| May 13, 2024 | Mar 1, 2024 | -0.07 | -0.05 | +0.02 | +28.57% |
| Apr 1, 2024 | Dec 1, 2023 | -0.05 | -0.06 | -0.01 | -20.00% |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.05 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.06 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Dec 9, 2024 | Ascendiant Capital | main | Buy | Buy |
| Nov 13, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- atossatherapeutics.com
News
Atossa Therapeutics Q3 EPS $(0.56) Beats $(0.90) Estimate
Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Confirms Shares To Begin Trading With One Stapled Contingent Value Right As Of Close Of Business On October 19
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers
Your note
Sign in to keep a note on ATOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FINN JONATHAN F. | Director | Purchase | Apr 9, 2024 | 25,000 |
| WEAVER GREGORY L | Officer and Director | Sale | Nov 14, 2023 | 55 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.68% | 9,667,615 | 9.96M | Sep 29, 2024 |
| Vanguard Group Inc | 5.25% | 6,598,296 | 6.80M | Sep 29, 2024 |
| Geode Capital Management, LLC | 2.24% | 2,814,446 | 2.90M | Sep 29, 2024 |
| State Street Corporation | 1.38% | 1,732,221 | 1.78M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.04% | 1,310,070 | 1.35M | Sep 29, 2024 |
| Northern Trust Corporation | 0.76% | 954,199 | 982.82K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.13% | 3,939,441 | 4.06M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.60% | 3,268,268 | 3.37M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.33% | 1,667,748 | 1.72M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 1.04% | 1,304,195 | 1.34M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.85% | 1,065,227 | 1.10M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.54% | 676,434 | 696.73K | Oct 30, 2024 |
